Skip Navigation

Skip Navigation

Issue No. 49  | November 16, 2012
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

Corrections to Pediatric ARV Treatment Guidelines

On November 15, 2012, additional changes were made to the Pediatric ARV Treatment Guidelines (released November 1, 2012):

  • In Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children, in Table 8, ETV was erroneously used as the abbreviation for etravirine. The table was amended with the correct abbreviation, ETR.
     
  • In the Appendix A record for etravirine, table title for pediatric dosing was updated to include weight with the age restriction. The title now reads: “Antiretroviral-experienced children and adolescents aged 6–18 years and weighing at least 16 kg.”
     
  • In the Appendix A record for etravirine, the statement advising against co-administering etravirine with other antiretroviral agents has been updated to include rilpivirine. The statement now reads: “It should not be administered with other non-nucleoside reverse transcriptase inhibitor (NNRTIs) (nevirapine, efavirenz, or rilpivirine).”


Recent News from FDA and NIH

The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) recently announced the following news:

  • November 14, 2012: Viramune XR (Nevirapine) Label Includes New 100 mg Tablet and Added Dosing Information

    “The FDA approved changes to the Viramune XR (nevirapine) Extended-Release Tablet label to include a new 100 mg tablet and dosing information in children 6 to less than 18 years of age."

    For more information, read the FDA press release.  

     
  • November 14, 2012: Prezista (Darunavir) Availability of 800 mg Tablet Strength

    “On November 9, 2012, FDA approved an 800 mg tablet strength for Prezista (darunavir), an HIV-1 protease inhibitor (PI) indicated for the treatment of HIV-1 infection.  The Dosage and Administration section has been changed, in part, to read: Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet or two 400 mg tablets) taken with ritonavir 100 mg once daily and with food."

    For more information, read the FDA press release.

     
  • November 9, 2012: 20 Percent of Youth with HIV Didn’t Know They Were Infected at First Sexual Experience

    “Roughly 20 percent of youth who have had HIV since birth did not know their HIV status when they first became sexually active, according to a study by a National Institutes of Health-supported research network.

    "The study also found that, of those youth who knew they had HIV and who were asked about disclosure of their HIV status to their first sexual partners, most reported that they had not told their partner prior to sexual activity.”

    For more information, read the NIH press release.
     


Happy Thanksgiving from AIDSinfo!

AIDSinfo At-a-Glance will not be published next week because of the Thanksgiving holiday. Our next scheduled At-a-Glance will be published on November 30.

We wish you and your family a safe and happy Thanksgiving!
 


Twitter - Stay connected FaceBook - Stay connected
ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228